Antitumor Effects of Oridonin on Xenograft Tumor of Human Papillary Thyroid Carcinoma in Nude Mice

This study aimed to evaluate the antitumor effects of oridonin (ORI) on xenograft tumor of human papillary thyroid carcinoma in nude mice. Human papillary thyroid carcinoma PTC-1 cells were implanted in nude mice to establish the xenograft tumor model. The modeled nude mice were randomly divided into Model, low-dose oridonin (ORI-L), middle-dose oridonin (ORI-M), high-dose oridonin (ORI-H) and doxorubicin (DOX) groups. The later 4 groups were treated with 10, 20, and 40 mg/kg ORI and 5 mg/kg DOX, respectively. The indicators related to animal and xenograft tumor growth and peripheral blood tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) levels were determined. After treatment, the body weight in DOX group was significantly lower than other groups, the tumor volume in ORI-M and OR I-H and DOX group w as significantly lower than Model and ORI-L groups, the inhibition rate in ORI-M and ORI-H groups was significantly higher than ORI-L group, the TNF-alpha and IL-2 levels in ORI-M and ORI-H groups were significantly higher than model group, and the kidney index and spleen index in ORI-L, ORI-M and ORI-H groups were significantly lower than DOX group (all P < 0.05). In conclusion, ORI has the antitumor effects on PTC-1 xenograft tumor in nude mice.